Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTIS2022-500849-24-00
CTIS2022-500849-24-00RecruitingPhase 1

TT-CSP-001

Tolremo Therapeutics AG0 sites25 target enrollmentStarted: June 23, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Enrollment
25
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 65+ (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Similar Trials

Active, not recruiting
Phase 1
This is clinical study to test, for the first time in people, the safety (anygood or bad effects), how long the drug can stay in the body and if it cancontrol the disease of people diagnosed with advanced cancer that has notresponded to treatment, has returned after it has been treated, or cannotbe treated by surgery, drugs, or any other known treatments.
CTIS2023-509969-20-00Celgene Corp.133
Active, not recruiting
Phase 1
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular disease
CTIS2024-510878-24-00Cereno Scientific AB48
Recruiting
Phase 1
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumours
CTIS2023-504199-19-00T3 Pharmaceuticals AG100
Active, not recruiting
Phase 1
A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Trial of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)Amyotrophic Lateral SclerosisMedDRA version: 21.1Level: PTClassification code: 10002026Term: Amyotrophic lateral sclerosis Class: 100000004852
CTIS2023-506174-12-00Itb-Med AB48
Active, not recruiting
Phase 1
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) - targeting, Bifunctional Antibody-fusion molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-Rich (START-001)nresectable, Locally Advanced, or Metastatic Solid Tumors
CTIS2023-505334-10-00Marengo Therapeutics Inc.271